Skip to main content

Infinity Pharmaceuticals, Inc. (INFI)

NASDAQ: INFI · IEX Real-Time Price · USD
3.72
+0.01 (0.27%)
After-hours:Sep 23, 2021 7:51 PM EDT
3.71
0.08 (2.20%)
At close: Sep 23, 4:00 PM
Market Cap329.15M
Revenue (ttm)1.91M
Net Income (ttm)-43.03M
Shares Out88.66M
EPS (ttm)-0.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,988,894
Open3.65
Previous Close3.63
Day's Range3.55 - 3.72
52-Week Range1.00 - 5.98
Beta2.20
AnalystsBuy
Price Target9.29 (+150.4%)
Est. Earnings DateNov 9, 2021

About INFI

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the d...

IndustryBiotechnology
CEOAdelene Perkins
Employees23
Stock ExchangeNASDAQ
Ticker SymbolINFI
Full Company Profile

Financial Performance

In 2020, INFI's revenue was $1.72 million, a decrease of -43.62% compared to the previous year's $3.05 million. Losses were -$40.49 million, -13.95% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 9.29, which is an increase of 150.40% from the latest price.

Price Target
$9.29
(150.40% upside)
Analyst Consensus: Buy

News

Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macropha...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

1 week ago - Business Wire

Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macroph...

2 weeks ago - Business Wire

Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

3 weeks ago - Business Wire

Hot Penny Stocks To Watch Making Big Moves This Week

Are these hot penny stocks on your watchlist right now? The post Hot Penny Stocks To Watch Making Big Moves This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:FAMI
4 weeks ago - PennyStocks

Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options

Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Best Biotech Penny Stocks For Your Monday Watchlist

With biotech penny stocks heating up, here are 3 you need to know about in August The post Best Biotech Penny Stocks For Your Monday Watchlist appeared first on Penny Stocks to Buy, Picks, News and Info...

Other symbols:ATOSEVFM
1 month ago - PennyStocks

Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...

1 month ago - Business Wire

Why Infinity Pharmaceuticals Blasted 38% Higher Today

A big investment bank took a new and very bullish view on the stock.

1 month ago - The Motley Fool

5 Blazing Buy-Rated Stocks Under $10 With Gigantic Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:ISKERNPAYOVKTX
1 month ago - 24/7 Wall Street

INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plunge

INFI stock is gaining nearly 50% today after two analysts said yesterday's data-driven drop created a buying opportunity. The post INFI Stock: Why Infinity Pharmaceuticals Is Soaring After Tuesday's Plu...

1 month ago - InvestorPlace

Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49 patients were enrolled in the MARIO-275 study d...

1 month ago - Benzinga

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MAR...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class...

1 month ago - Business Wire

Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...

1 month ago - Business Wire

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

2 months ago - Business Wire

Infinity to Present at The Keystone Symposia Precision Oncology Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

3 months ago - Business Wire

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:CASIISRPDSBSVRA
4 months ago - 24/7 Wall Street

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Infinity Pharmaceuticals: Q1 Earnings Insights

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which ...

4 months ago - Benzinga

Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially firs...

4 months ago - Business Wire

Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

4 months ago - Business Wire

Infinity to Present at New York Academy of Sciences' Frontiers in Cancer Immunotherapy 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

4 months ago - Business Wire

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...

4 months ago - Business Wire